FORMULATION AND OPTIMIZATION OF CHITOSAN NANOPARTICLES OF DIMETHYL FUMARATE USING BOX-BEHNKEN DESIGN
Objective: Dimethyl fumarate (DMF) is a methyl ester of fumaric acid. It has been approved by USFDA recently for the treatment of an autoimmune disorder, multiple sclerosis (MS). The objective of present study was to synthesize and optimize chitosan loaded nanoparticles of DMF by box-behnken design (BBD), to provide a better drug delivery system for the management and treatment of MS.
Methods: Polyelectrolyte complex coacervation technique was used to prepare Chitosan (CS) loaded DMF nanoparticles and box behnken design using 3 factors and 3 levels were selected for optimization of the formulation. Effect of three independent factors that is, polymer CS concentration, polymer dextran sulfate (DS) concentration and the amount of drug were studied on two dependent responses that is particle size and % drug entrapment efficiency. The analysis of variance (ANOVA) was performed to evaluate the significant differences between the independent variables.
Results: The optimized batch showed the highest % drug entrapment (65.36) and an average particle size (355 nm). Zeta potential value was optimum to maintain the stability of the formulation. In vitro drug release behavior followed Korsmeyer-Peppas model which showed the initial release of 21.7Â±1.3% with prolonged drug release of 69.5Â±0.8% from optimized CS nanoparticle up to 24 h. The % cumulative drug release (% CDR) of optimized nanoparticles was 84%.
Conclusion: The optimized nanoparticles of DMF with improved properties could be a promising formulation for the treatment and management of MS.
Keywords: Multiple sclerosis, dimethyl fumarate, chitosan nanoparticle, optimization, box behnken design, complex polyelectrolyte conservation.
2. Gerard J Tortora, Bryan Derrickson. The principle of anatomy and pathophysiology. WikiInternational. 11th Edition; 2009. p. 433-4.
3. Margaret F, Bennewitz, Mark Saltzman W. Nanotechnology for the delivery of drugs to the brain for epilepsy. J Nutr 2009;6:323â€“36.
4. Kappos L, Radue EM, Oâ€™Connor P, Polman C, Hohlfeld R, Calabresi P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362:87.
5. Navikas V, Link H. Review. Cytokines and the pathogenesis of multiple sclerosis. J Neurosci Res 1996;45:322â€“33.
6. http://www.fda.gov/medwatch. [Last accessed on 14 May 2015].
7. Oriella GA, Domenico M, Antonio S, Stefania A, Lucia G. Determination of dimethyl fumarate in desiccant and anti mould sachets by reversedâ€phase liquid chromatography. Biomed Chromatogr 2011;25:1315â€“8.
8. Tiyaboonchai W, Limpeanchob. Formulation and characterization of amphotericin B chitosan-dextran sulphate nanoparticles. N Int J Pharm 2007;329:142â€“9.
9. Solanki AB, Parikh JR, Parikh RH. Formulation and optimization of piroxicamproniosomes by 3-factor, 3-level box-behnken design. AAPS PharmSciTech 2007;E1-E8:43.
10. Bilati U, Allemand E, Doelker E. Development of a nanoprecipitation method intended for the entrapment of hydrophilic drugs into nanoparticles. Eur J Pharm Sci 2005;24:67â€“75.
11. Quintanar D, Guerrero, Allemand E, Fessi H, Doelker E. Preparation techniques and mechanisms of formation of biodegradable nanoparticles from preformed polymers. Drug Dev Ind Pharm 1998;12:1113â€“28.
12. Cheng J, Teply BA, Sherifi I. Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. Biomaterials 2007;28:869â€“76.
13. Tokumitsu H, Ichikawa H, Fukumori Y. Chitosan-gadopentetic acid complex nanoparticles for gadolinium neutron capture therapy of cancer: preparation by novel emulsion droplet coalescence technique and characterization. Pharm Res 1999;16:1830-5.
14. Krishna A, Shilaja, Amareshwar P, Chakravarty P. Differents techniques used for the preparation of nanoparticles using natural polymers and their application. Int J Pharm Pharm Sci 2011;3:45-50.
15. Nagavarma BVN, Hemant KSY, Ayaz A, Vasudha LS, Shivakumar HG. Different techniques for preparation of polymeric nanoparticles-a review. Asian J Pharm Clin Res 2012;5 Suppl 3:16-23.
16. Sarmento B, Martins S, Ribeiro A, Veiga F, Neufeld R, Ferreira D. Development and comparison of different nanoparticulate polyelectrolyte complexes as insulin carriers. Int J Pept Res Ther 2015;12:131-8.
17. Ferreira SL, Bruns RE, Ferreira HS. Box-behnken design: an alternative for the optimization of analytical methods. Anal Chim Acta 2007;597:179â€“86.
18. Gopi G, Kannan K. Formulation development, and optimization of nateglinide loaded ethyl cellulose nanoparticles by box-behnken design. Int J Pharm Pharm Sci 2015;7:311-5.
19. Nagpal K, Singh SK, Mishra DN. Optimization of the brain targeted chitosan nanoparticles of Rivastigmine for improved efficacy and safety. Inventi Rapid 2012;19:378-91.
20. Wang J, Tan H, Yu A, Ling P, Lou H, Zhai G, et al. Preparation of chitosan-based nanoparticles for delivery of low molecular weight heparin. J Biomed Nanotechnol 2011;7:696â€“703.
21. Yu Baojie, Zhang Long, Du Changhai. Determination of the purity of dimethyl fumarate by UV spectrophotometry. Guangzhou Chem 1999;1:32-4.
22. Raja Namasivayam SK, George Robin A. Preparation, optimization and characterization of biocompatible nano albumin-ofloxacin (bsanp-of) conjugate and evaluation of control release, antibacterial activity against a clinical isolate of pseudomonas aeruginosa. Asian J Pharm Clin Res 2013;6:235-9.